Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome

V. Ďurovcová, J. Marek, V. Hána, M. Matoulek, V. Zikán, D. Haluzíková, P. Kaválková, Z. Lacinová, M. Kršek, M. Haluzík

. 2010 ; 59 (3) : 415-422.

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc11000416

Grantová podpora
NR9438 MZ0 CEP - Centrální evidence projektů

The objective of this study was to measure plasma fibroblast growth factor 21 and 19 (FGF21 and FGF19) levels in patients with Cushing's syndrome (CS) and to compare it with those of lean control subjects (C) and patients with obesity (OB). Fourteen untreated patients with CS, 19 patients with OB and 36 controls were included in the study. Plasma FGF21 and FGF19 levels were measured by ELISA kits, other hormonal and biochemical parameters were measured by standard laboratory methods. Plasma FGF19 did not significantly differ among the studied groups. Plasma FGF21 levels were significantly higher in both CS and OB groups relative to C group but they did not differ between CS and OB groups. In a combined population of all three groups FGF21 levels positively correlated with BMI, waist circumference and percentage of total and truncal fat mass. Less prominent inverse relationship with these parameters was found for FGF19. Neither FGF21 nor FGF19 were significantly related to cortisol concentrations. Increased FGF21 concentrations in both patients with CS and OB relative to lean subjects suggest that excessive body fat and/or related metabolic abnormalities rather than direct effects of cortisol are responsible. In contrast neither obesity nor hypercortisolism significantly affected FGF19 concentrations.

Citace poskytuje Crossref.org

Bibliografie atd.

Lit.: 25

000      
00000naa 2200000 a 4500
001      
bmc11000416
003      
CZ-PrNML
005      
20140724085635.0
008      
110201s2010 xr e eng||
009      
AR
024    7_
$a 10.33549/physiolres.931801 $2 doi
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ďurovcová, Viktória $7 xx0118444
245    10
$a Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome / $c V. Ďurovcová, J. Marek, V. Hána, M. Matoulek, V. Zikán, D. Haluzíková, P. Kaválková, Z. Lacinová, M. Kršek, M. Haluzík
314    __
$a Third Dept. Med., First Fac. Med., Charles Univ. & Gen. Univ. Hosp., Prague
504    __
$a Lit.: 25
520    9_
$a The objective of this study was to measure plasma fibroblast growth factor 21 and 19 (FGF21 and FGF19) levels in patients with Cushing's syndrome (CS) and to compare it with those of lean control subjects (C) and patients with obesity (OB). Fourteen untreated patients with CS, 19 patients with OB and 36 controls were included in the study. Plasma FGF21 and FGF19 levels were measured by ELISA kits, other hormonal and biochemical parameters were measured by standard laboratory methods. Plasma FGF19 did not significantly differ among the studied groups. Plasma FGF21 levels were significantly higher in both CS and OB groups relative to C group but they did not differ between CS and OB groups. In a combined population of all three groups FGF21 levels positively correlated with BMI, waist circumference and percentage of total and truncal fat mass. Less prominent inverse relationship with these parameters was found for FGF19. Neither FGF21 nor FGF19 were significantly related to cortisol concentrations. Increased FGF21 concentrations in both patients with CS and OB relative to lean subjects suggest that excessive body fat and/or related metabolic abnormalities rather than direct effects of cortisol are responsible. In contrast neither obesity nor hypercortisolism significantly affected FGF19 concentrations.
650    _2
$a financování organizované $7 D005381
650    _2
$a adipozita $7 D050154
650    _2
$a dospělí $7 D000328
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a Cushingův syndrom $x krev $x patofyziologie $7 D003480
650    _2
$a ELISA $7 D004797
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblastové růstové faktory $x krev $7 D005346
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a hydrokortison $x krev $7 D006854
650    _2
$a lidé středního věku $7 D008875
650    _2
$a obezita $x krev $x patofyziologie $7 D009765
650    _2
$a obvod pasu $7 D055105
700    1_
$a Marek, Josef, $d 1936-2019 $7 nlk19990073526
700    1_
$a Hána, Václav, $d 1956- $7 xx0018430
700    1_
$a Matoulek, Martin, $d 1972- $7 xx0080325
700    1_
$a Zikán, Vít $7 xx0074463
700    1_
$a Haluzíková, Denisa, $d 1970- $7 jo2003163140
700    1_
$a Kaválková, Petra $7 xx0094376
700    1_
$a Lacinová, Zdeňka $7 xx0062138
700    1_
$a Kršek, Michal $7 xx0046428
700    1_
$a Haluzík, Martin, $d 1970- $7 xx0000707
773    0_
$w MED00003824 $t Physiological research $g Roč. 59, č. 3 (2010), s. 415-422 $x 0862-8408
856    41
$u http://www.biomed.cas.cz/physiolres/pdf/59/59_415.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 4120 $c 266 $y 7 $z 0
990    __
$a 20110131162710 $b ABA008
991    __
$a 20140724085945 $b ABA008
999    __
$a ok $b bmc $g 827407 $s 692279
BAS    __
$a 3
BMC    __
$a 2010 $b 59 $c 3 $m Physiological research $x MED00003824 $d 415-422
GRA    __
$a NR9438 $p MZ0
LZP    __
$a 2011-05/dkme

Najít záznam

Citační ukazatele

Nahrávání dat ...